WHAT IS CLAIMED IS:

1. A composition comprising an aqueous medium having dispersed or dissolved therein

a glutathione and an NAD or derivative thereof, wherein the glutathione is at an amount from about 0.01% to 0.9%, and wherein the NAD or derivative thereof is at an amount from about 0.01% to 0.9%.

2. A composition of claim 1, wherein the composition further comprises an analgesic selected from the group consisting white willow bark, aspirin, ibuprofen, naproxen, and any combination thereof in an amount of from about 0.001% to about 0.35% by weight; and

feverfew dried plant particles dispersed or dissolved in the aqueous medium having a concentration of about 0.001 to 2.0% in the aqueous medium.

3. The composition of claim 1, wherein the NAD or derivative thereof is nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); or nicotinamide adenine dinucleotide, reduced form (NADH).

4. The composition of claim 1, wherein the NAD or NAD derivative is selected from the group consisting of quinolinic acid; quinolinic acid ribonucleotide; nicotinamide; nicotinic acid; nicotinic acid ribonucleotide; nicotinic acid ribonucleotide, reduced form; nicotinamide ribonucleotide; nicotinamide ribonucleotide, reduced form; nicotinic acid adenine dinucleotide; nicotinic acid adenine dinucleotide, reduced form; nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP);

nicotinamide adenine dinucleotide, reduced form (NADH); and nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) and pharmaceutically acceptable salts thereof.

5. The composition of claim 1, wherein the glutathione is tripeptide L-glutathione (GSH) (gamma-glutamyl-cysteinyl-glycine or a dimer (GSSG).

6. The composition of claim 1, wherein the glutathione amount is 0.2%.

7. The composition of claim 2, wherein the feverfew is present at a concentration of about 0.01% to 0.35%.

8. The composition of claim 7, wherein the feverfew is present at a concentration of 0.10%.

9. The composition of claim 1, wherein the composition further comprises an agent selected from the group consisting of butterbur extract, goldenseal extract, dandelion extract, polyporous extract, ascorbic acid, potassium sorbate, and any combination thereof.

10. The composition of claim 1, further comprising a material selected from the group consisting of a surfactant, a vitamin, a vitamin derivative, a wetting agent, a preservative, and an emulsifier.

11. The composition of claim 10, wherein the emulsifier is glycerin.

12. The composition of claim 2, wherein the analgesic agent is white willow bark.

13. A method of treating a subject suffering from an oxidative disease or disorder, comprising administering a composition of claim 1.

14. A method of treating as subject suffering from Parkinson's disease, comprising administering to a mucus membrane of the subject a composition comprising:

an aqueous medium;

a glutathione and an NAD or derivative thereof, wherein the glutathione is at an amount from about 0.01% to 0.9%, and wherein the NAD or derivative thereof is at an amount from about 0.01% to 0.9% in the aqueous medium; and

wherein the composition is administered in an amount effective to reduce the severity and/or treat the symptoms of Parkinson's disease.

15. The method of claim 14, wherein the composition further comprises an analgesic selected from the group consisting white willow bark, aspirin, ibuprofen, naproxen, and any combination thereof in an amount of from about 0.001% to about 0.35% by weight; and

feverfew dried plant particles dispersed or dissolved in the aqueous medium having a concentration of about 0.001 to 2.0% in the aqueous medium.

16. The method of claim 14, wherein the NAD or derivative thereof is nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); or nicotinamide adenine dinucleotide, reduced form (NADH).

17. The method of claim 14, wherein the NAD or NAD derivative is selected from the group consisting of quinolinic acid; quinolinic acid ribonucleotide; nicotinamide; nicotinic acid; nicotinic acid ribonucleotide; nicotinic acid ribonucleotide, reduced form; nicotinamide ribonucleotide; nicotinamide ribonucleotide, reduced form; nicotinic acid adenine dinucleotide; nicotinic acid adenine dinucleotide, reduced form; nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); nicotinamide adenine dinucleotide, reduced form (NADH); and nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) and pharmaceutically acceptable salts thereof.

18. The method of claim 14, wherein the glutathione is tripeptide L-glutathione (GSH) (gamma-glutamyl-cysteinyl-glycine or a dimer (GSSG).

19. The method of claim 14, wherein the glutathione amount is 0.2%.

20. The method of claim 15, wherein the feverfew is present at a concentration of about 0.01% to 0.35%.

21. The method of claim 20, wherein the feverfew is present at a concentration of 0.10%.

22. The method of claim 14, wherein the composition further comprises an agent selected from the group consisting of butterbur extract, goldenseal extract, dandelion extract, polyporous extract, ascorbic acid, potassium sorbate, and any combination thereof.

23. The method of claim 14, further comprising a material selected from the group consisting of a surfactant, a vitamin, a vitamin derivative, a wetting agent, a preservative, and an emulsifier.

24. The method of claim 23, wherein the emulsifier is glycerin.

25 The method of claim 15, wherein the analgesic agent is white willow bark.

26. A nasal spray comprising the composition of claim 1.

27. A sublingual spray comprising the composition of claim 1.

28. The composition of claim 1, wherein the NAD or NAD derivative is at about 0.2%.

29. The method of claim 14, wherein the NAD or NAD derivative is at about 0.2%.